SLU-PP-332 is an experimental small molecule — not a peptide — that activates estrogen-related receptors (ERRs), the switches that turn on genes for building mitochondria and burning fat. In mouse studies, it produced a muscle gene profile resembling endurance training, increased running endurance and reduced fat gain in obese animals. There are no human studies, so its benefits, proper dosing and safety in people are unknown, and it is not FDA-approved.
What Is SLU-PP-332?
SLU-PP-332 was developed by academic researchers studying how to mimic the metabolic effects of exercise with a drug. It is a synthetic agonist of the estrogen-related receptors ERRα, ERRβ and ERRγ, with particular activity at ERRα.
Despite the name, estrogen-related receptors do not respond to estrogen. They are "orphan" nuclear receptors that help control energy metabolism, and they are highly active in tissues with heavy energy demands: skeletal muscle, heart, kidney and brown fat.
Because it is often sold online next to peptides, many people assume SLU-PP-332 is one. It is not; it is a small molecule with very different chemistry, including poor water solubility.
How SLU-PP-332 Works
Earlier patient materials I wrote used an analogy that still holds up: think of your genome as a vast library of blueprints, with ERRα acting as a senior librarian for everything related to energy production.
- ERRα activation. SLU-PP-332 binds and activates ERRα — waking up the librarian.
- Partnership with PGC-1α. ERRα works with a coactivator called PGC-1α, a master regulator of mitochondrial biogenesis. Together they amplify the signal.
- Mitochondrial gene program. The complex switches on genes for the electron transport chain, fatty acid oxidation and the TCA cycle.
- Metabolic shift. Muscle moves toward a more oxidative, fat-burning profile, with more fatigue-resistant fiber characteristics.
Exercise is the most powerful natural trigger for this same pathway. That is why SLU-PP-332 is called an "exercise mimetic." For the bigger picture, see The Role of Mitochondrial Health in Aging.
What the Research Shows
Everything we know comes from preclinical work, primarily two mouse studies:
- A 2023 study in ACS Chemical Biology reported that treated sedentary mice ran roughly 70% longer than controls, and their muscle showed an exercise-like gene expression profile that depended on ERRα.
- A 2024 study in the Journal of Pharmacology and Experimental Therapeutics found that obese mice gained less fat and had improved insulin sensitivity. Lean mice did not show the same glucose benefit.
In these studies, the compound was given by injection into the abdominal cavity of mice — a route not used in people — at doses that cannot simply be translated to humans.
Correcting Common Claims
Online material about SLU-PP-332 frequently goes far beyond the evidence. A few corrections:
- "It fixes the root cause of chronic disease." Mitochondrial dysfunction, insulin resistance and inflammation are connected, and the framework is useful. But no human study shows that SLU-PP-332 corrects any of them in people.
- "It replaces exercise." Mice showed some exercise-like gene changes. Exercise also strengthens the heart, bones and tendons, improves balance, lowers blood pressure, and benefits mood and cognition. No compound has been shown to reproduce that.
- "It protects against viruses, Alzheimer's or heart disease." These claims are extrapolations from cell or animal work on the ERR pathway, not studies of SLU-PP-332 in humans.
- Preparation and injection advice. Because the compound dissolves poorly in water, some sellers recommend dissolving it in solvents such as DMSO and injecting it. There is no established safe human formulation, dose or route. Please do not attempt this.
Safety Unknowns
Because there are no human studies, the honest answer to "Is it safe?" is that we don't know. Specific open questions include:
- Cardiac effects. ERRs are highly active in the heart. Long-term pharmacological activation has not been evaluated for cardiac safety.
- Cancer. Pathways that increase cellular energy production may also support tumor growth; this has not been studied.
- Liver and kidney effects of chronic exposure.
- Product quality. It is sold only as a research chemical, with no pharmaceutical quality standards.
- Athletes. Anti-doping rules broadly prohibit metabolic modulators; competitive athletes should check with their governing body.
Regulatory Status
SLU-PP-332 is not FDA-approved, has no publicly known investigational new drug application or human trial, and is not a dietary supplement or a compounding ingredient. It is sold online only as a research chemical "not for human use."
What I Recommend Instead
The pathway SLU-PP-332 targets is real and important — and you already have access to the most powerful way to activate it. Consistent aerobic training, especially sustained moderate-intensity work, drives mitochondrial biogenesis through the same PGC-1α pathway; Zone 2 Cardio: The Longevity Exercise Protocol explains how. Resistance training, sleep and metabolic health complete the picture. For patients interested in mitochondrial biology, MOTS-c is another compound often discussed, with its own evidence limits.
At Laeeq M.D., I am genuinely interested in exercise-mimetic research, and I follow it closely. But my recommendations are based on what has been shown to help people. Right now, for SLU-PP-332, that evidence does not exist.
Sources
- Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity — Billon C, et al. ACS Chemical Biology, 2023
Book a Consultation
If you are looking for ways to improve energy, endurance or metabolic health, a physician evaluation can identify what will actually move the needle for you. Dr. Laeeq offers 60-minute consultations, virtually or in person in Reston, VA. Book a consultation to build an evidence-based plan.
This article is for educational purposes and is not medical advice. Discuss any treatment with a licensed physician who knows your history.
Frequently asked questions
Written by Dr. Laeeq Ahmed Butt, M.D., MBA
Board-certified internist practicing peptide and longevity medicine in Reston, VA, with virtual care in seven states. About Dr. Laeeq